Experimentation of cancer therapies:
Substantial revenue growth and buoyant momentum in
Over the first six months of 2014, the portion of Experimentation revenue recorded outside
Discovery of new kinase inhibitors
Acceleration in in-house discovery programs thanks to the IPO
Over the 1st half of 2014, revenue from research collaboration, notably with IPSEN, Sanofi and UCB, totaled €0.53m, compared with €0.63m a year earlier. These figures correspond to the reimbursement of R&D costs paid by
Oncodesign’s in-house TGFbR2, SIK2 and RIP2 kinases discovery programs were accelerated in accordance with the objectives of the IPO carried out in
These R&D efforts will be continued and stepped up over the 2nd half of 2014 in order to accelerate the selection of new drug candidates on these targets of interest in oncology and inflammatory diseases.
Net cash position of €10.8m, cash burn limited to €1.5m over the half year
Net cash burn, excluding the costs associated with the IPO, totaled €1.5m over the 1st half of 2014. This limited figure is notably the result of Oncodesign’s balanced and resilient business model, which combines state-of-the-art R&D activities and repeat revenue from its experimentation services activities.
“This first half of 2014 marked a major milestone in Oncodesign’s development. As well as our achievements in our business activities, our IPO enabled us to obtain the necessary financial means to successfully execute our business plan and continue our permanent innovation approach aimed at helping as many patients as possible. We are notably striving to support the acceleration of our discovery programs in the promising field of kinase inhibitors and to strengthen the commercial deployment of our experimentation activities in